期刊
CLINICAL INFECTIOUS DISEASES
卷 76, 期 7, 页码 1161-1163出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciad061
关键词
malaria; travel; artesunate; Plasmodium falciparum; chemoprophylaxis
The increase in international travel during the COVID-19 pandemic recovery period is expected to lead to an increase in imported malaria cases in the US. Prevention, timely diagnosis, and appropriate treatment are crucial in minimizing imported malaria morbidity and mortality. Intravenous artesunate (IVAS) is now available for severe malaria treatment in the US. Hospitals and pharmacists should have a malaria treatment plan that includes stocking artemether-lumefantrine for uncomplicated malaria and ensuring access to IVAS for severe cases.
Return to international travel in the COVID-19 pandemic recovery period is expected to increase the number of patients with imported malaria in the United States (US). Malaria prevention in travelers and preparedness for timely diagnosis and appropriate treatment are key to minimize imported malaria morbidity and mortality. Intravenous artesunate (IVAS) is now available from commercial distributors in the US for the treatment of severe malaria. Hospitals and pharmacists should have a plan for malaria treatment, including stocking artemether-lumefantrine for uncomplicated malaria, and stocking or planning for rapid procurement of IVAS for the treatment of severe malaria.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据